Axicabtagene ciloleucel
gilead,daiichi sankyo
['zuma-1,(-zuma-12),(-zuma-14)', 'axi-cel', 'lymsm', 'lymphoma']
congress | #ash22 caron a jacobson presented results from a pilot study of axi-cel in 9 pts with r/r cnsl. cr rate of 67% with acceptable safety was observed. med time to best response was 3 months.
#lymsm #medicalcongress #hematology 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm